USANA Health Sciences (NYSE:USNA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15, Zacks reports. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. USANA Health Sciences updated its FY 2025 guidance to 2.350-3.000 EPS.
USANA Health Sciences Trading Up 3.2 %
USNA stock traded up $0.91 during midday trading on Friday, reaching $29.55. The company had a trading volume of 299,854 shares, compared to its average volume of 166,624. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32. The company has a market capitalization of $563.22 million, a P/E ratio of 10.44, a PEG ratio of 0.93 and a beta of 0.87. The company has a 50 day moving average of $33.50 and a two-hundred day moving average of $36.56.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on USNA. DA Davidson cut their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. Finally, StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.
Check Out Our Latest Research Report on USANA Health Sciences
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
